1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mangalam Drugs & Organics Ltd.

Mangalam Drugs & Organics Ltd.

29.57
INR
-0.85
(-2.79%)
-24.16EPS
445.41MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
92.97
167.39
205.19
192.26
176.36
141.49
178.3
239.95
282.64
231.21
230.91
199.13
145.5
146.6
Basic EPS, GAAP
-2.31
4.66
11.15
14.07
12.57
-5.07
5.21
17.67
12.42
0.8
-5.73
4.25
-28.05
-24.16
Free Cash Flow per Basic Share
3.93
7.7
7.45
2.07
5.42
7.8
14.92
-2.46
-1.24
7.33
-5
14.15
-4.88
- -
Dividend per Share
- -
- -
- -
- -
0.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
17.62
22.28
43.17
54.15
65.56
60.44
65.67
82.63
95.12
96
85.79
94.12
65.11
- -
Tangible Book Value per Share
17.62
22.28
43.13
54.12
65.08
58.06
61.79
76.34
86.42
84.48
67.79
74.88
44.27
- -
Basic Weighted Avg Shares
13
13
14
16
16
16
16
16
16
16
16
16
16
16
Sales/Revenue/Turnover
1,225
2,206
2,950
3,043
2,792
2,239
2,822
3,798
4,474
3,660
3,655
3,152
2,303
2,320
Operating Margin (%)
4.76
7.38
11.33
13.7
14.43
1.18
5.5
11.7
8.66
3.99
0.29
5.33
-14.03
-11.56
Depreciation Expense
40
42
44
50
66
75
82
92
102
110
75
166
182
178
Net Income, GAAP
-30
61
160
223
199
-80
83
280
197
13
-91
67
-444
-382
Effective Tax Rate (%)
- -
- -
33.24
28.56
32.23
- -
- -
29.22
29.12
42.63
- -
- -
- -
- -
Profit Margin (%)
-2.48
2.78
5.43
7.32
7.13
-3.59
2.92
7.36
4.39
0.35
-2.48
2.13
-19.28
-16.48
Working Capital
100
166
269
180
230
142
97
248
549
412
119
74
-409
- -
LT Debt
402
394
169
169
111
105
50
101
303
255
185
117
86
- -
Total Equity
232
294
621
857
1,038
957
1,039
1,308
1,506
1,520
1,358
1,490
1,031
- -
Return on Invested Capital (%)
- -
- -
20.07
21.69
17.4
- -
- -
17.65
12.46
3.47
- -
- -
- -
- -
Return on Capital (%)
- -
- -
18.22
19.76
15.85
- -
- -
18.21
11.28
2.67
- -
- -
- -
- -
Return on Common Equity (%)
-12.28
23.36
35.07
30.15
20.99
-8.05
8.27
23.83
13.97
0.84
-6.31
4.72
-35.23
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
1,042
- -
LT Borrowings
- -
75
- -
LT Finance Leases
- -
11
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
435
430
445

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,557
- -
Cash, Cash Equivalents & STI
- -
39
- -
Accounts Receivable, Net
- -
403
- -
Inventories
- -
1,028
- -
Total Current Liabilities
- -
1,966
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,042
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.01%
-3.14%
-30.82%
Free Cash Flow
-131.58%
-285.47%
-134.48%
Net Income, GAAP
-194.83%
-374.46%
-760.65%
Sales/Revenue/Turnover
-0.55%
-8.25%
-26.93%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
765
798
886
728
3,152
2026
572
493
584
673
2,303
2027
571
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
1.7
1.7
0.81
0.04
4.25
2026
-8.72
-4.64
-6.21
-8.48
-28.05
2027
-4.83
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Govardhan Murlidhar Dhoot
Full Time Employees
319
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Rupam Building Mumbai MA India 400 001
IPO Date
Apr 19, 2005
Website
mangalamdrugs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mangalam Drugs & Organics Limited manufactures active pharmaceutical ingredients (APIs), intermediates, specialty chemicals, organic and inorganic chemicals; and provides regulatory services to pharmaceutical companies worldwide. The company produces anti-malarial APIs including artemether, lumefantrine, and artemisinin-based compounds; cardiovascular products such as atorvastatin calcium; antiviral agents like acyclovir and dolutegravir sodium; central nervous system drugs including aripiprazole, risperidone, olanzapine, and etodolac; and perfumery chemicals such as l(+)menthol and phthalazine-1,4-dione. It operates multi-product manufacturing facilities in Vapi, Gujarat, and additional sites in India, with an in-house Research & Development laboratory recognized by the Department of Scientific & Industrial Research, Government of India. Founded in 1972 and headquartered in Mumbai, Maharashtra, Mangalam Drugs & Organics Limited serves global markets in Asia, Africa, Europe, and the Americas, positioning itself among Asia's top producers and the world's largest for select anti-malarial APIs. The company maintains certifications including WHO-Geneva GMP, EDQM, MFDS Korea, and ANVISA approvals for its plants, and holds an ongoing agreement with the Clinton Health Access Initiative under its Fight Malaria Program for anti-malarial API supply. In recent developments, Mangalam Drugs & Organics Limited inks a technology transfer deal with Emzor Pharmaceutical Industries Limited for four anti-malarial APIs to support manufacturing in Africa. The company agrees to acquire Shri JB Pharma LLP in March 2024 via a scheme of merger involving issuance of 265 equity shares, pending National Company Law Tribunal and stakeholder approvals. It achieves WHO prequalification for dolutegravir sodium (non-micronised and micronised forms) in October 2020 and participates in the Medicines Patent Pool pledge with 17 other generic manufacturers to accelerate COVID-19 interventions for low- and middle-income countries.